Posted on 8440
Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care, disinfectant use and dermatological conditions, and Microderm Technologies Ltd. announce that Dermodacyn® disinfectant has received import clearance as a medical device for Thailand with the help from Microderm’s partner VetSynova Co. Ltd., Thailand, and is now available online and in pharmacies and stores in Hong Kong and Thailand.
Dermodacyn disinfecting solution is designed to be sprayed as an aerosol to disinfect areas suspected to contain bacteria and viruses that can lead to disease. Dermodacyn disinfectant is medical grade and can be used in hospitals to keep doctors and patients protected and safe. It also performs well in other high traffic areas that require constan
Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) resulting from allegations that Sonoma may have issued materially misleading business information to the investing public.
WOODSTOCK, Ga. (BUSINESS WIRE) Jan 11, 2021
Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, disinfectant use and dermatological conditions, today announced that CEO Amy Trombly and CFO Jerry Dvonch will present at the H.C. Wainwright Bioconnect 2021 Virtual Conference taking place January 11-14, 2021.
The presentation is available for on-demand listening beginning at 6:00 AM Eastern Time on Monday, January 11, 2021, through close of business January 14, 2021. For those interested in viewing Sonoma’s presentation, registration can be accessed . In addition, the presentation was furnished on a current report on Form 8-K with the U.S. Securities and Exchange Commission via EDGAR.
ROSEN, A LEADING INVESTOR FIRM, Continues To Investigate Securities Claims Against Sonoma Pharmaceuticals, Inc tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
FinancialBuzz.com’s latest
The Buzz Show: Featuring Our Corporate News Recap on “Ocugen Inc. Surges After Announcing Binding Letter of Intent with Bharat Biotech”
Ocugen Inc. (NASDAQ: OCGN) shot up over 63% in premarket trading after announcing a binding letter of intent with Bharat Biotech to develop the latter’s COVAXIN vaccine candidate for the United States market.
COVAXIN™ has been evaluated in approximately 1,000 subjects in Phase 1 and Phase 2 clinical trials in India and is currently part of a Phase 3 clinical trial involving 26,000 volunteers.
Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related ma